Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 74, Pages S19-S23 (December 2008)

Similar presentations


Presentation on theme: "Volume 74, Pages S19-S23 (December 2008)"— Presentation transcript:

1 Volume 74, Pages S19-S23 (December 2008)
Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide  Begoña López, Arantxa González, Nerea Hermida, Concepción Laviades, Javier Díez  Kidney International  Volume 74, Pages S19-S23 (December 2008) DOI: /ki Copyright © 2008 International Society of Nephrology Terms and Conditions

2 Figure 1 Myocardial fibrosis in chronic kidney disease. Microscopic image of the myocardium of a patient with stage 3 chronic kidney disease, arterial hypertension and left ventricular hypertrophy showing interstitial (arrow) and perivascular (arrowhead) deposition of collagen fibers stained with picrosirius red. (Original magnification × 20.) Kidney International  , S19-S23DOI: ( /ki ) Copyright © 2008 International Society of Nephrology Terms and Conditions

3 Figure 2 Diastolic dysfunction in chronic kidney disease. Prevalence of diastolic dysfunction, as assessed by tissue Doppler imaging, in the different stages of chronic kidney disease. TDI, tissue Doppler imaging. (Adapted from de Almeida et al.10) Kidney International  , S19-S23DOI: ( /ki ) Copyright © 2008 International Society of Nephrology Terms and Conditions

4 Figure 3 Effects of loop diuretics on myocardial fibrosis in chronic heart failure. Effects of torasemide and furosemide on myocardial collagen volume fraction (CVF) (left panel) and procollagen type I carboxy-terminal proteinase (PCP) activation (right panel) in patients with chronic heart failure. (Adapted from López et al.29, 32) Kidney International  , S19-S23DOI: ( /ki ) Copyright © 2008 International Society of Nephrology Terms and Conditions

5 Figure 4 Mechanisms and consequences of the myocardial antifibrotic effects of torasemide. Proposed cardioprotection afforded by torasemide in patients with chronic kidney disease (CKD). HTN, hypertension; PCP, procollagen type I carboxy-terminal proteinase; LV, left ventricular; and HF, heart failure. Kidney International  , S19-S23DOI: ( /ki ) Copyright © 2008 International Society of Nephrology Terms and Conditions


Download ppt "Volume 74, Pages S19-S23 (December 2008)"

Similar presentations


Ads by Google